# Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

> **NCT00101816** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 124 (actual)

## Conditions studied

- Chronic Myeloid Leukemia
- Blast Crisis

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00101816
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2006-08
- **Final completion:** 2008-03
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2010-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101816, "Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00101816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*